Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference32 articles.
1. Piotrowska Z, Isozaki H, Lennerz JK, Gainor JF, Lennes IT, Zhu VW et al (2018) Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov 8(12):1529–1539
2. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3(75):75ra26.
3. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6(10):1118–1133
4. Rivard PE, Elwy AR, Loveland S, Zhao S, Tsilimingras D, Elixhauser A et al (2005) Applying patient safety indicators (PSIs) across health care systems: achieving data comparability. In: Henriksen K, Battles JB, Marks ES, Lewin DI (eds) Advances in patient safety: from research to implementation, vol. 2: concepts and methodology. Advances in Patient Safety, Rockville.
5. Chera BS, Mazur L, Buchanan I, Kim HJ, Rockwell J, Milowsky MI et al (2015) Improving patient safety in clinical oncology: applying lessons from normal accident theory. JAMA Oncol 1(7):958–964
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献